Financial Performance - Fourth quarter revenues increased 116% to $91.1 million compared to the fourth quarter of 2023 [1] - Full year revenues increased 473% to $290.5 million compared to 2023 [1] - Net income for the fourth quarter was $45.5 million, or $1.58 per common share (basic) [20] - Net income for the full year was $89.2 million, or $3.12 per common share (basic) [20] - Gross margin for the fourth quarter was 95% [7] Business Developments - The Company received full sanctioning of the KB407 Phase 1 protocol from the Cystic Fibrosis Foundation Therapeutic Development Network [1][8] - The Company has secured over 510 reimbursement approvals for VYJUVEK in the U.S. [7] - The Company is focused on executing the global launch of VYJUVEK and advancing multiple clinical stage programs in 2025 [2] Clinical Pipeline - VYJUVEK is indicated for the treatment of Dystrophic Epidermolysis Bullosa (DEB) [3][22] - The Company has enrolled approximately 50 DEB patients in a natural history study for KB803, with a Phase 3 study expected to commence in 1H 2025 [5] - KB407 is being evaluated in a Phase 1 study for cystic fibrosis, with interim data expected in mid-2025 [8][9] - KB408 for alpha-1 antitrypsin deficiency has shown promising initial data, with results from expanded cohorts expected in 2H 2025 [9] - Inhaled KB707 for lung tumors has shown an objective response rate of 27% in advanced non-small cell lung cancer patients [11] Financial Guidance - The Company projects non-GAAP combined R&D and SG&A expenses for FY 2025 to be between $150 million and $175 million [18]

Core Points - Krystal Biotech, Inc. will report its fourth quarter and full year 2024 financial results on February 19, 2025, before U.S. market opens [1] - A conference call and webcast will be hosted by the company's management at 8:30 am ET on the same day to discuss the financial results and provide a business update [1] Company Overview - Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines for diseases with high unmet medical needs [3] - The company's first commercial product, VYJUVEK®, is the first-ever redosable gene therapy and the first FDA-approved medicine for treating dystrophic epidermolysis bullosa [3] - The company is advancing a robust pipeline of investigational genetic medicines across various fields including respiratory, oncology, dermatology, ophthalmology, and aesthetics [3]

Group 1 - The stock of Krystal Biotech, Inc. (KRYS) is experiencing significant attention due to high implied volatility in the options market, particularly for the Feb. 21, 2025 $100 Call option [1] - Implied volatility indicates the market's expectation of future price movement, suggesting that investors anticipate a significant change in the stock's price, potentially due to an upcoming event [2] - Krystal Biotech currently holds a Zacks Rank 4 (Hold) in the Medical - Biomedical and Genetics industry, which is in the top 31% of the Zacks Industry Rank, with no changes in earnings estimates from analysts over the last 60 days [3] Group 2 - The high implied volatility surrounding Krystal Biotech may indicate a developing trading opportunity, as options traders often seek to sell premium on such options to capture decay, hoping the stock does not move as much as expected by expiration [4]

PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and c ...

Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

Krystal Biotech (KRYS) announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.The phase I/II KYANITE-1 study is evaluating the safety, tolerability and tumor response (measured using RECIST v1.1 criteria) of inhaled KB707 as a monotherapy in 37 patients with malignant lesions in the lung. Out of the total enrolled patient population, 17 were diagnosed with advanced non-small cell lung ...

Preliminary clinical data in post-anti-PD-1 NSCLC patients demonstrated a 27% ORR and 73% DCR in monotherapy trial Monotherapy activity with inhaled KB707 provides further evidence of successful repeat administration of HSV-1 based inhaled lung gene delivery and builds on recent clinical data update for CF and AAT deficiency respiratory disease programs PITTSBURGH, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced tod ...

Krystal Biotech, Inc. (KRYS) announced initial clinical data updates on its two inhaled genetic medicine pipeline candidates, KB407 and KB408, which are being developed in early-stage studies for treating rare respiratory diseases.Shares of the company were down 7.3% on Dec. 12 following the announcement of the news.KB407 is being developed in a phase I study for the treatment of cystic fibrosis (CF), while KB408 is being developed in a phase I study for treating alpha-1 antitrypsin deficiency (AATD).The la ...

A month has gone by since the last earnings report for Krystal Biotech, Inc. (KRYS) . Shares have added about 6.6% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Krystal Biotech due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Krystal Q3 Earnings and Sales Top Estim ...

PITTSBURGH, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in fireside chats and host investor meetings at two upcoming investor conferences: Citi’s 2024 Global Healthcare Conference on December 3, 2024 in Miami, Florida; fireside chat scheduled for 8:45 am ET7th Annual Evercore HealthCONx Conference on December 4, 2024 in Coral Gable ...